FDA Approves Tirzepatide as First Drug to Treat Obstructive Sleep Apnea Itself
Start here
The FDA has approved tirzepatide (Zepbound), a GLP-1/GIP dual receptor agonist, as the first drug to treat obstructive sleep apnea directly, rather than just its symptoms; previously approved drugs such as modafinil addressed only daytime sleepiness. In adults with moderate-to-severe OSA (AHI of at least 15) and BMI over 30, the 52-week SURMOUNT OSA trial showed tirzepatide reduced AHI by about 20 events per hour more than placebo, with weight loss of roughly 18-20%. At the 15 mg weekly dose, OSA resolution occurred in 43% of patients unable to tolerate CPAP and 51.5% of CPAP users. The label carries a boxed warning on thyroid C-cell tumors.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comFDA Approves Tirzepatide (Zepbound) as First Drug to Treat Obstructive Sleep Apnea
The FDA has approved tirzepatide (Zepbound), a GLP-1/GIP dual receptor agonist, as the first drug to treat obstructive sleep apnea itself, whereas prior approved drugs such as modafinil only addressed daytime sleepiness. In the 52-week SURMOUNT OSA trial in adults with moderate-to-severe OSA (AHI at least 15) and BMI over 30, tirzepatide cut AHI about 20 events per hour more than placebo, with weight loss of roughly 18-20%. At the 15 mg weekly dose, OSA resolution occurred in 43% of those unable to tolerate CPAP and 51.5% of CPAP users; the label carries a boxed warning on thyroid C-cell tumors.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.